Digital therapy support provider Mika closes funding round
The Berlin-based health start-up Fosanis, provider of the Mika app, has successfully closed another round of funding. Investors are Ananda Impact Ventures, Evodia and IBB Ventures.
Mika provides support for cancer patients when facing the greatest challenge of their life. Mika’s digital therapy is clinically proven, user-centred, patient empowering and the first German company in this field to be approved as a medical device.
The existing investors are also the investors in this financing round:
- Ananda Impact Ventures
- Evodia
- IBB Ventures
Fosanis will use the raised capital to further develop its product and to accelerate the distribution of the Mika app. In addition, Fosanis will advance the scientific studies on the effectiveness of Mika.
The company is also seeking inclusion in the directory for digital health apps (DiGa) in Germany. Approval by the Federal Institute for Drugs and Medical Devices (BfArM) will make Mika an “app on prescription”. After receiving the approval, statutory health insurance funds will reimburse the costs for digital therapy support. Fosanis expects to be listed at the end of Q1/beginning of Q2.
Dr. Bernd Klosterkemper, Partner at Ananda Impact Ventures, explains:
“Mika has great potential for us to contribute to better care for cancer patients in a data-driven and digital way. Mika has developed a key position at the interface of patients, doctors, insurance companies and pharmaceutical companies and we are proud to be able to accompany Mika on its way to DiGA”
We at Ananda Impact Ventures congratulate the Mika team around the founders Gandolf Finke and Jan Simon Raue as well as our co-investors IBB Ventures and Evodia.
Read more about the funding round here (Handelsblatt): https://bit.ly/30SVJV7
